• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision regarding whether or not to stop taking ADHD medication during pregnancy and breastfeeding. There is a lack of information about how long-term exposure to these medications can affect the foetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological issues like hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge that further high-quality research is needed.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication should evaluate the benefits of using it against the potential risks to the fetus. Doctors don't have the data needed to make unequivocal recommendations however they can provide information on the risks and benefits to help pregnant women make informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy were not at a higher risk of fetal malformations, or structural birth defects. Researchers conducted a large population-based study of case control to assess the frequency of structural defects that were major in infants born to mothers who were taking stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts looked over the cases to ensure that the classification was accurate and to eliminate any bias.

The study conducted by the researchers had some limitations. The researchers were not able to, in the first place to distinguish the effects of the medication from the disorder. This limitation makes it difficult for researchers to determine whether the small differences observed between the groups exposed were due to the use of medication or caused by the presence of comorbidities. In addition the researchers did not study the long-term outcomes of offspring.

The study did reveal that babies whose mothers had taken ADHD medication during pregnancy were at a slightly more risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or cut back on their medications prior to or during pregnancy. This was due to central nervous system-related disorders and the higher risk of admission did not appear to be influenced by which stimulant medications were used during pregnancy.

Women who took stimulant ADHD medication during pregnancy were also at an increased risk of having a caesarean delivery or having a child with a low Apgar score (less than 7). These increases did appear to be independent of the type of medication taken during pregnancy.

Researchers suggest that the minor risks posed by the use of adhd medication online uk medication during pregnancies in the early stages could be offset by the greater benefits for baby and mother of continued treatment for the woman's condition. Physicians should discuss this with their patients and, where possible, help them develop strategies to improve coping skills that may minimize the effects of her disorder on her daily functioning and relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and being treated with medication, the issue of whether to keep or discontinue treatment during pregnancy is one that more and more doctors have to face. These decisions are often made without clear and authoritative evidence. Instead, doctors must consider their own expertise and experience, as well as the experiences of other doctors, and the research on the topic.

In particular, the issue of potential risks to the baby can be a challenge. The research on this subject is based on observations instead of controlled studies and a lot of the results are conflicting. In addition, most effective adhd medication for adults uk studies limit their analysis to live births, which can underestimate severe teratogenic effects that cause abortion or termination of the pregnancy. The study discussed in the journal club addresses these shortcomings by analyzing both data on live and deceased births.

The conclusion: While some studies have found an association between ADHD medications and the possibility of certain birth defects, other studies have found no such relationship and the majority of studies show a neutral or even slight negative effect. In each case it is imperative to conduct a thorough analysis of the benefits and risks should be conducted.

It isn't easy, but not impossible for women suffering from ADHD to stop taking their medication. In fact, in a recent article in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of isolation, and family conflict for these patients. Furthermore, a loss of medication can interfere with the ability to do work-related tasks and safely drive which are essential aspects of daily life for a lot of people with ADHD.

She suggests that women who are unsure about whether to keep or stop medication in light of their pregnancy consider educating family members, friends and colleagues on the condition, its effects on daily functioning, and the benefits of keeping the current treatment plan. It can also help the woman feel supported as she struggles with her decision. Certain medications can pass through the placenta. If a patient decides not to take her ADHD medication while pregnant and breastfeeding, it's important to be aware that the drug could be transferred to the infant.

Risk of Birth Defects

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows as do concerns over the impact that these drugs might have on foetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. With two massive data sets researchers were able to analyze more than 4.3 million pregnancies to determine whether the use of stimulant medications increased the risk of birth defects. While the overall risk is low, the researchers did find that first-trimester exposure to ADHD medications was linked to an increased risk of specific heart defects, such as ventriculoseptal defect (VSD).

The researchers of the study found no connection between early use of medication and other congenital anomalies, such as facial clefting or club foot. The findings are in line with previous studies showing an increase, but not significant, in the risk of cardiac malformations among women who started taking ADHD medications prior to the time of pregnancy. The risk increased in the latter half of pregnancy, when a lot of women stopped taking their medication.

Women who were taking ADHD medication in the first trimester were more likely require a caesarean delivery, have a low Apgar after delivery and had a baby that required breathing assistance after birth. However the researchers of the study were unable to eliminate bias due to selection by limiting the study to women who didn't have any other medical issues that could have contributed to these findings.

Researchers hope that their research will provide doctors with information when they see pregnant women. They suggest that although discussing risks and benefits is important but the decision to stop or keep medication should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors warn that, while stopping the medication is an option to think about, it isn't recommended due to the high prevalence of depression and mental health issues among women who are pregnant or who have recently given birth. Further, the research suggests that women who decide to stop their medications are more likely to experience difficulties adapting to life without them after the birth of their baby.

Nursing

The responsibilities that come with being a new mother can be overwhelming. Women who suffer from ADHD who prescribes medication for adhd have to manage their symptoms while attending doctor appointments and making preparations for the arrival of a baby and adapting to new routines in the home may face a lot of challenges. Therefore, many women elect to continue taking their Adhd medication over The counter uk medication throughout the pregnancy.

The majority of stimulant medicines pass through breast milk in low amounts, so the risk to the breastfeeding infant is minimal. However, the rate of exposure to medication by the infant can differ based on dosage, how often it is taken and the time of the day it is administered. Additionally, different medications enter the baby’s system via the gastrointestinal tract, or through breast milk. The effect on the health of a newborn isn't completely known.

Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the lack of research. It is a difficult decision for the woman who must weigh the advantages of her medication against the potential risks to the fetus. As long as more information is available, doctors can inquire about pregnant patients whether they have a history of ADHD or if they intend to take medication during the perinatal period.

A increasing number of studies have shown that women can continue taking their ADHD medication during pregnancy and breastfeeding. This has led to many patients are choosing to do so and after consulting with their doctor, they have discovered that the benefits of keeping their current medication outweigh any risks.

It's important for women with ADHD who are thinking of breastfeeding to seek out a specialist psychiatrist's advice prior becoming pregnant. They should review their medications with their physician and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation should also be offered to help women with ADHD recognize their symptoms and the root cause, learn about available treatment options and reinforce existing coping strategies. This should be a multidisciplinary effort with the GPs, obstetricians, and psychiatry. Pregnancy counseling should consist of a discussion of a treatment plan for the mother as well as the child, [empty] monitoring of indicators of deterioration, and, if necessary adjustments to the medication regime.